STOCK TITAN

The9 (NASDAQ: NCTY) expects stake in Nasdaq-bound AI drug company

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

The9 Limited (NCTY) reports that its investee Nanyang Biologics (NYB), an AI-driven drug discovery company in which The9 holds a strategic stake through subsidiary Gamenow.net, has cleared a key step toward a planned Nasdaq listing. Shareholders of RF Acquisition Corp II (RFAI) approved NYB’s proposed business combination at an extraordinary general meeting held on August 19, 2026, a transaction that would list the combined company on Nasdaq under ticker “NYB,” subject to customary closing conditions. Upon completion, The9 expects to hold approximately 15%–16% of the combined Nasdaq-listed company. NYB’s Vecura™ AI platform uses a proprietary library of more than one million natural compounds to identify novel bioactive drug candidates, aligning with The9’s strategy to extend beyond its core AI-powered gaming ecosystem into broader AI-enabled industries.

Positive

  • Upon completion of the NYB–RFAI business combination, The9 expects to own 15%–16% of a Nasdaq-listed AI drug discovery company, expanding its exposure to AI-driven life sciences.
  • Shareholder approval of the NYB business combination at RFAI’s extraordinary general meeting removes a major procedural hurdle toward NYB’s planned Nasdaq listing.

Negative

  • None.

Filing Explained

NYB’s combination received shareholder approval, but The9’s expected 15% to 16% stake remains conditional on closing.

The company reports that RFAI shareholders approved NYB’s proposed business combination on August 19, 2026, but the combination remains subject to customary closing conditions, so it has not been disclosed as completed.

If the combination closes, The9 is expected to hold approximately 15% to 16% of the combined Nasdaq-listed company through its wholly owned subsidiary Gamenow; the filing therefore advances the investment toward potential public-company ownership without establishing that ownership today.

The next material milestone is satisfaction of the customary closing conditions and completion of the business combination, which the filing leaves unresolved.

Expected ownership in combined Nasdaq-listed NYB 15% to 16% The9’s anticipated stake upon completion of the NYB–RFAI business combination
Date of RFAI shareholder approval meeting August 19, 2026 Extraordinary general meeting where RFAI shareholders approved NYB’s proposed business combination
Size of NYB natural compound library More than one million natural compounds Underlying dataset for NYB’s Vecura™ AI drug discovery platform
Planned ticker symbol for combined company NYB Reserved ticker for the combined, Nasdaq-listed company after the business combination
extraordinary general meeting regulatory
"At an extraordinary general meeting held on August 19, 2026, shareholders of RF Acquisition Corp II"
business combination financial
"shareholders of RF Acquisition Corp II voted to approve NYB’s proposed business combination"
A business combination happens when two or more companies join together to operate as one, like two friends merging their teams into a single group. This is important because it can change how companies grow, compete, and make money, often making them bigger and more powerful in the market.
AI-driven drug discovery medical
"a Singapore-based, AI-driven drug discovery company in which The9 holds a strategic equity stake"
AI-driven drug discovery uses advanced computer programs to spot promising drug targets and molecules by analyzing large sets of biological and chemical data, accelerating steps that used to take many years of lab work. Investors care because it can cut research costs, shorten development timelines and raise the odds of finding viable medicines—think of it as using a smart metal detector to find valuable items more efficiently than digging at random—while still carrying scientific and regulatory risk.
Vecura™ AI platform technical
"Its Vecura™ AI platform, built on a proprietary library of more than one million natural compounds"
digital asset tokens financial
"volatility in the market price of digital assets, the limited liquidity of certain digital asset tokens"

FAQ

What did The9 Limited (NCTY) announce regarding Nanyang Biologics (NYB)?

The9 announced that Nanyang Biologics’ proposed business combination with RF Acquisition Corp II was approved at an extraordinary general meeting on August 19, 2026, marking a key step toward NYB becoming a Nasdaq-listed company under the ticker “NYB,” subject to customary closing conditions.

How large will The9’s stake in the combined Nasdaq-listed NYB be?

The9 expects to hold approximately 15%–16% of the combined company after completion of the NYB–RF Acquisition Corp II business combination, giving The9 a significant minority position in the planned Nasdaq-listed AI-driven drug discovery company.

What type of business is Nanyang Biologics (NYB), The9’s investee company?

NYB is a Singapore-based, AI-driven drug discovery company. It uses its Vecura™ AI platform and a proprietary library of more than one million natural compounds to identify promising bioactive drug candidates and mechanisms that conventional synthetic-first approaches may overlook.

How does the NYB investment fit into The9 Limited (NCTY)’s strategy?

The9 describes its NYB stake as part of a strategy of selectively extending into promising AI-driven opportunities beyond its core AI gaming ecosystem, the9bit, as it builds a multi-engine business across AI-empowered industries and the broader digital ecosystem.

What conditions remain before NYB is listed on Nasdaq according to The9 (NCTY)?

The9 states that completion of the NYB and RF Acquisition Corp II business combination remains subject to customary closing conditions. Only after those conditions are satisfied would NYB become a Nasdaq-listed company under ticker “NYB.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER 

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER 

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2026

 

 

 

Commission File Number: 001-34238

 

 

 

THE9 LIMITED

 

17 Floor, No. 130 Wu Song Road 

Hong Kou District, Shanghai 200080 

People’s Republic of China 

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x       Form 40-F ¨

 

 

 

 

 

Explanatory Note

 

This current report on Form 6-K, including the exhibits hereto, is incorporated by reference into the amendment No. 4 to the registration statement on Form F-3 (File No. 333-295089) and shall be a part of such registration statement from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release – The9’s Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  THE9 LIMITED
       
  By       :

/s/ George Lai

  Name: : George Lai
  Title: : Director and Chief Executive Officer

 

Date: August 21, 2026

 

 

 

 

 

Exhibit 99.1

 

The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

 

Milestone Marks Further Progress in The9's Strategic Investment in AI-Driven Drug Discovery; The9 Expects to Hold Approximately 15% to 16% of the Combined, Nasdaq-Listed Company

 

HONG KONG, August 21, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) (“The9” or the “Company”), a global, diversified high-tech company, today announced that Nanyang Biologics Pte. Ltd. (“NYB”), a Singapore-based, AI-driven drug discovery company in which The9 holds a strategic equity stake, has taken a significant step toward its planned Nasdaq listing. At an extraordinary general meeting held on August 19, 2026, shareholders of RF Acquisition Corp II (“RFAI”) voted to approve NYB’s proposed business combination, marking a key milestone in NYB’s effort to become a Nasdaq-listed company under the reserved ticker symbol “NYB.”

 

The9, which holds a stake in NYB through its wholly owned subsidiary Gamenow.net (Hong Kong) Limited (“Gamenow”), previously announced the investment as part of the Company’s strategy of selectively extending into promising AI-driven opportunities beyond its core gaming ecosystem, the9bit. Upon completion of the business combination, which remains subject to customary closing conditions, The9 is expected to hold approximately 15% to 16% of the combined, Nasdaq-listed company.

 

NYB specializes in applying artificial intelligence to the discovery of novel drug candidates from natural compounds. Its Vecura™ AI platform, built on a proprietary library of more than one million natural compounds, is designed to identify promising bioactive candidates and mechanisms that conventional, synthetic-first approaches often overlook.

 

“This vote is an encouraging step forward for NYB and reflects strong shareholder confidence in its business,” said George Lai, Chief Executive Officer of The9. “As a long-term investor in NYB, we are pleased to see this investment move closer to the public markets. We see this progress as more than a milestone for NYB alone; it reinforces the value of our investment and widens the range of possibilities for us going forward as we continue to build out The9's presence across the AI sector.”

 

About The9 Limited

 

The9 Limited (Nasdaq: NCTY) is a global, diversified high-tech company redefining how games are created, played, and monetized. Founded in 1999 and Nasdaq-listed since 2004, The9 brings over two decades of gaming heritage to its flagship platform the9bit, an AI-powered digital asset ecosystem built around AI game creation and the $9BIT token economy, where every participant can play, create, earn, and own a stake in its growth. Beyond the9bit, The9 continues to explore emerging opportunities across AI-empowered industries and the broader digital ecosystem, including an equity stake in AI-driven drug discovery company NYB, building a multi-engine business positioned at the frontier of AI and the new economy, reshaping how value is created and shared.

 

No Offer or Solicitation

 

This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

 

 

 

Forward-Looking Statements

 

This release contains statements that are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management's beliefs and expectations as well as on assumptions made by and data currently available to management, and they appear in a number of places throughout this document and include statements regarding, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. The use of the words "will," "expects," "intends," "anticipates," "estimates," "predicts," "believes," "should," "potential," "may," "forecast," "objective," "plan," or "target," and other similar expressions are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties that could cause actual results to differ materially. Such statements include, but are not limited to, statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies, future market conditions or economic performance and developments in the capital and credit markets, expected future financial performance, and the markets in which we operate. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including, but not limited to, the following: results of operations, financial condition, our stock price, our strategies, our future business development, competition in the industry in which we operate, our ability to manage our costs and expenses, volatility in the market price of digital assets, the limited liquidity of certain digital asset tokens, evolving and uncertain regulatory frameworks governing cryptocurrencies, digital assets, and token-based economies, laws and regulations relating to the industry in which we operate, general economic and business conditions, and assumptions underlying or related to any of the foregoing. For a discussion of these and other risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statement, see The9's filings with the U.S. Securities and Exchange Commission. The9 undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

 

Investor Relations Contact

 

Ms. Jojo Su 

Investor Relations Specialist 

The9 Limited 

Tel: +86 (21) 6108-6080 

Email: IR@corp.the9.com

 

Ms. Helen Wu 

Piacente Financial Communications 

Tel: +86 (10) 6508-0677 

Email: The9@thepiacentegroup.com

 

 

 

 

 

Filing Exhibits & Attachments

1 document